SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mendonca J.)
 

Sökning: WFRF:(Mendonca J.) > C5F glial markers a...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005648naa a2200841 4500
001oai:gup.ub.gu.se/320875
003SwePub
008240528s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:150922684
024a https://gup.ub.gu.se/publication/3208752 URI
024a https://doi.org/10.1002/acn3.516722 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1509226842 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Woollacott, I. O. C.4 aut
2451 0a C5F glial markers are elevated in a subset of patients with genetic frontotemporal dementia
264 c 2022-10-17
264 1b Wiley,c 2022
520 a Background: Neuroinflammation has been shown to be an important pathophysiological disease mechanism in frontotemporal dementia (FTD). This includes activation of microglia, a process that can be measured in life through assaying different glia-derived biomarkers in cerebrospinal fluid. However, only a few studies so far have taken place in FTD, and even fewer focusing on the genetic forms of FTD. Methods: We investigated the cerebrospinal fluid concentrations of TREM2, YKL-40 and chitotriosidase using immunoassays in 183 participants from the Genetic FTD Initiative (GENFI) study: 49 C9orf72 (36 presymptomatic, 13 symptomatic), 49 GRN (37 presymptomatic, 12 symptomatic) and 23 MAPT (16 presymptomatic, 7 symptomatic) mutation carriers and 62 mutation-negative controls. Concentrations were compared between groups using a linear regression model adjusting for age and sex, with 95% bias-corrected bootstrapped confidence intervals. Concentrations in each group were correlated with the Mini-Mental State Examination (MMSE) score using non-parametric partial correlations adjusting for age. Age-adjusted z-scores were also created for the concentration of markers in each participant, investigating how many had a value above the 95th percentile of controls. Results: Only chitotriosidase in symptomatic GRN mutation carriers had a concentration significantly higher than controls. No group had higher TREM2 or YKL-40 concentrations than controls after adjusting for age and sex. There was a significant negative correlation of chitotriosidase concentration with MMSE in presymptomatic GRN mutation carriers. In the symptomatic groups, for TREM2 31% of C9orf72, 25% of GRN, and 14% of MAPT mutation carriers had a concentration above the 95th percentile of controls. For YKL-40 this was 8% C9orf72, 8% GRN and 0% MAPT mutation carriers, whilst for chitotriosidase it was 23% C9orf72, 50% GRN, and 29% MAPT mutation carriers. Conclusions: Although chitotriosidase concentrations in GRN mutation carriers were the only significantly raised glia-derived biomarker as a group, a subset of mutation carriers in all three groups, particularly for chitotriosidase and TREM2, had elevated concentrations. Further work is required to understand the variability in concentrations and the extent of neuroinflammation across the genetic forms of FTD. However, the current findings suggest limited utility of these measures in forthcoming trials.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
653 a lobar degeneration
653 a fluid biomarkers
653 a microglia
653 a injury
653 a genfi
653 a Neurosciences & Neurology
700a Swift, I. J.4 aut
700a Sogorb-Esteve, A.4 aut
700a Heller, C.4 aut
700a Knowles, K.4 aut
700a Bouzigues, A.4 aut
700a Russell, L. L.4 aut
700a Peakman, G.4 aut
700a Greaves, C. V.4 aut
700a Convery, R.4 aut
700a Heslegrave, A.4 aut
700a Rowe, J. B.4 aut
700a Borroni, B.4 aut
700a Galimberti, D.4 aut
700a Tiraboschi, P.4 aut
700a Masellis, M.4 aut
700a Tartaglia, M. C.4 aut
700a Finger, E.4 aut
700a van Swieten, J. C.4 aut
700a Seelaar, H.4 aut
700a Jiskoot, L.4 aut
700a Sorbi, S.4 aut
700a Butler, C. R.4 aut
700a Graff, C.u Karolinska Institutet4 aut
700a Gerhard, A.4 aut
700a Laforce, R.4 aut
700a Sanchez-Valle, R.4 aut
700a de Mendonca, A.4 aut
700a Moreno, F.4 aut
700a Synofzik, M.4 aut
700a Vandenberghe, R.4 aut
700a Ducharme, S.4 aut
700a Le Ber, I.4 aut
700a Levin, J.4 aut
700a Otto, M.4 aut
700a Pasquier, F.4 aut
700a Santana, I.4 aut
700a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe
700a Rohrer, J. D.4 aut
710a Karolinska Institutetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org
773t Annals of Clinical and Translational Neurologyd : Wileyg 9:11, s. 1764-1777q 9:11<1764-1777x 2328-9503
8564 8u https://gup.ub.gu.se/publication/320875
8564 8u https://doi.org/10.1002/acn3.51672
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:150922684

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy